Telemedicine prescribing of controlled substances: pandemic-era flexibilities and their extensions
DEA, together with HHS, permitted prescribing of certain controlled substances via telemedicine without a prior in-person evaluation, and extended those flexibilities through a series of temporary rules while permanent rulemaking remained under consideration. Because these rules have been repeatedly extended and amended, Ketalux does not assert a current expiration date.
This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.
Record details
- Agency
- DEA
- Jurisdiction
- United States (federal)
- Status
- Verify current status
- Published
- March 2020 (initial flexibilities), extended by subsequent temporary rules
- Effective
- Not applicable / not verified
- Expires
- Not applicable / not verified
- Last checked
- August 24, 2026
Why it matters
Whether an at-home oral ketamine program can lawfully prescribe without an in-person exam depends on the rule in force at the time — plus state law, which can be stricter than federal law.
Primary source
Back to the Regulatory Tracker.
Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.